Ketogenic Diet Shows Promise in Treating Psychotic Disorders

A groundbreaking randomized controlled trial (RCT) published today in *Schizophrenia Bulletin* explores the efficacy of a ketogenic diet in managing psychotic disorders, offering the first clinical evidence of its potential benefits for individuals with schizophrenia-spectrum or bipolar 1 disorders. Conducted by researchers at the University of California, San Francisco (UCSF), the study demonstrates that a ketogenic diet—a high-fat, low-carbohydrate regimen—can yield rapid metabolic improvements compared to standard dietary practices. The trial’s initial one-month open-label phase revealed significant metabolic enhancements, prompting further investigation into the diet’s broader therapeutic effects.

The study enrolled participants with schizophrenia-spectrum or bipolar 1 disorders and followed a two-phase design. During the first month, those assigned to the ketogenic diet showed faster improvements in metabolic markers than those following their usual diets. An optional four-month single-arm extension phase, in which participants adhered exclusively to the ketogenic diet, revealed additional gains in psychiatric symptoms, cognitive function, and metabolic health. While the extension lacked a control group, the consistency of improvements across multiple domains suggests the diet’s potential as a complementary intervention. Researchers emphasize the need for larger, controlled trials to confirm these findings and establish long-term safety.

This study adds to emerging research on non-pharmacological approaches for managing psychiatric conditions. If validated, the ketogenic diet could offer a novel, low-cost strategy to address both the metabolic and clinical challenges faced by individuals with severe mental illness. The findings underscore the importance of interdisciplinary collaboration in advancing treatment options for populations with complex health needs.